Clinical trials: Acute Upper Gastrointestinal Bleeding
Acute Upper Gastrointestinal Hemorrhage, Acute Upper Gastrointestinal Bleeding
Clinical Investigation of Safety and Performance of a Medical Device (ClearPlasma) for the Treatment of Patients With Acute Upper Gastrointestinal Hemorrhage.
Pre-market, multi-center, international, double-blind, randomized, controlled, prospective, first-in-human clinical investigation of a Class IIb Investigational Medical Device, in which Patients presenting with acute upper…
- Trial name
- NCT04174989
- Testing
- Plasma treated with ClearPlasma (Extra-corporeal plasma filtration device), Regular fresh-frozen plasma (not treated)
- Where
- 8 sites in Czechia, Israel and 1 more
- Volunteers
- 53 people
- Sponsor
- PlasFree Ltd.
Acute Coronary Syndrome, Myocardial Infarction
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- COGENT-1 (NCT00557921)
- Testing
- CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
- Where
- 491 sites in United States, Australia and 14 more
- Volunteers
- 5,000 people
- Sponsor
- Cogentus Pharmaceuticals
Acute Gastrointestinal Bleeding
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding
A prospective, multi-center, noninferiority randomized controlled trial designed to compare the efficacy of UI-EWD (Nexpowder™) hemostatic powder versus conventional endoscopic hemostatic therapy in patients presenting with acute…
- Trial name
- TREET (NCT06188585)
- Testing
- UI-EWD, Conventional therapy
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 278 people
- Sponsor
- Medtronic - MITG
Upper Gastrointestinal Bleeding (UGIB)
Evaluation of ClearPlasma in Patients With Upper Gastrointestinal Bleeding.
Upper gastrointestinal hemorrhage (UGIH) is one of the most common gastrointestinal emergencies, and is associated with significant morbidity and mortality. Plas-Free aims to evaluate ClearPlasma safety in patients with UGIH.
- Trial name
- CLearPlasma (NCT06761430)
- Testing
- ClearPlasma
- Where
- Italy
- Volunteers
- 7 people
- Sponsor
- PlasFree Ltd.
Gastrointestinal Hemorrhage
Efficacy and Safety Study of Esomeprazole vs Omeprazole to Treat Acute Non-Variceal Upper Gastrointestinal Bleeding
The purpose of this study is to assess the efficacy and safety of Esomeprazole and Omeprazole intravenous every 12 hours for 5 days in subjects with acute non-variceal upper gastrointestinal bleeding
- Trial name
- NCT00402259
- Testing
- Esomeprazole IV, Omeprazole IV
- Where
- 7 sites in China
- Volunteers
- 440 people
- Sponsor
- AstraZeneca
Upper Gastrointestinal Bleeding
Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding
The purpose of this study is to determine and analyse the incidence, severity, risk factors and routine management of acute drug-induced upper gastrointestinal bleeding (UGIB) in the population of Russian patients
- Trial name
- NCT01155401
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Upper Gastrointestinal Hemorrhage
A Pilot and Feasibility Study to Evaluate Capsule Endoscopy
This study is aimed at assessing the capability of the PillCam Platform using the PillCam ESO 2 Capsule in: Determining whether there is 1) active bleeding in the Upper gastrointestinal (UGI) tract, 2) identifying the anatomic…
- Trial name
- MA-79 (NCT00974701)
- Testing
- PillCam ESO2
- Where
- 2 sites in Hong Kong, Israel
- Volunteers
- 50 people
- Sponsor
- Medtronic - MITG
Peptic Ulcer
Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding
To assess the efficacy and safety of the early administration of somatostatin in infusion during 72 hours plus 2 boluses, compared to placebo in the control of acute severe UGIB with suspicion of PUB.
- Trial name
- NCT00152399
- Testing
- Somatostatin UCB (drug)
- Where
- 22 sites in Belgium, France and 4 more
- Volunteers
- 370 people
- Sponsor
- UCB Pharma